Secondary validation for rAbs consists of IP analysis of cell extracts spiked with purified target protein. For mAbs, this validation consists of IP and WB analysis of target proteins expressed in human cell lines using a doxycycline-dependent promoter. Selected reagents are further tested by third-party validation at the National Cancer Institute (NCI), which has demonstrated good reproducibility for reagents obtained both directly from production labs and from third-party distributors. Over 250 IP-grade mAbs have also been tested for ChIP-Seq. Since this validation pipeline is high throughput, additional user optimization may be necessary for some reagents.
The PCRP has developed a web portal (http://proteincapture. org/) to catalog passing rAbs and mAbs and to make all validation results available. This allows users to select the best reagent for their intended experiment, although further tests and/or optimization may be necessary. PCRP reagents are distributed at low cost through the University of Iowa Developmental Studies Hybridoma Bank (DSHB) (http://dshb.biology.uiowa.edu/), CDI Laboratories (www.cdi-lab.com), and a number of third-party commercial distributors. DNA constructs for each rAb can also be obtained through the DNASU plasmid repository (https://dnasu. org/). Direct links to distributors are available on the PCRP portal.
The PCRP has produced a combined total of over 1,500 rAbs and mAbs (Supplementary Table 1 ). The use of these well-characterized, renewable affinity reagents is likely to reduce costs and improve reproducibility for studies of hTF function. Furthermore, we hope that this effort serves as a template for future undertakings aimed at developing specific affinity reagents for the rest of the human proteome. 
